Comparative Pharmacology
Head-to-head clinical analysis: SYMADINE versus TRIFLURIDINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SYMADINE versus TRIFLURIDINE.
SYMADINE vs TRIFLURIDINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
SYMADINE (amantadine) is a tricyclic amine that inhibits influenza A virus replication by blocking the viral M2 ion channel, which prevents uncoating of viral RNA. It also increases dopamine release and inhibits dopamine reuptake in the CNS, providing antiparkinsonian effects.
Trifluridine is a thymidine analog that inhibits thymidylate synthase and incorporates into DNA, leading to DNA damage and cell death.
100 mg orally every 12 hours; immediate-release formulation.
Topical: Apply one drop to affected eye every 2 hours while awake (maximum 9 drops/day) until re-epithelialization, then one drop every 4 hours for 7 days. Ophthalmic solution 1%.
None Documented
None Documented
Clinical Note
moderateTrifluridine + Digoxin
"Trifluridine may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateTrifluridine + Digitoxin
"Trifluridine may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateTrifluridine + Deslanoside
"Trifluridine may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateTrifluridine + Acetyldigitoxin
"Trifluridine may decrease the cardiotoxic activities of Acetyldigitoxin."
The terminal elimination half-life is approximately 24 hours in patients with normal renal function. In patients with renal impairment (CrCl <50 mL/min), the half-life is significantly prolonged, requiring dose adjustment. The long half-life allows for once-daily dosing.
The terminal elimination half-life of trifluridine is approximately 12-18 hours. This prolonged half-life supports twice-daily dosing and provides sustained exposure for antiviral activity.
Renal elimination of unchanged drug accounts for approximately 90% of the administered dose. Biliary/fecal excretion is minimal (<5%).
Renal excretion accounts for approximately 40-50% of the administered dose, primarily as the inactive metabolite 5-trifluorothymidine. Fecal excretion is minimal (<5%). The remainder is eliminated via metabolic degradation.
Category C
Category C
Antiviral and Antiparkinsonian
Antiviral